Literature DB >> 1514552

Superior vena cava syndrome associated with lymphoma.

A Yellin1, M Mandel, G Rechavi, Y Neuman, B Ramot, Y Lieberman.   

Abstract

OBJECTIVE: To evaluate the workup and treatment of children with lymphoma and superior vena cava syndrome.
DESIGN: A retrospective survey.
SETTING: State hospital serving as a secondary and tertiary referral center for pediatric oncology and pediatric cardiac surgery. PARTICIPANTS: Eleven children aged 11 months to 12 years diagnosed as having lymphoma or T-cell acute lymphoblastic leukemia who presented with superior vena cava syndrome during an 11-year period.
INTERVENTIONS: Lymph node biopsy (two patients), thoracenthesis (five patients), bone marrow aspiration (two patients), and thoracenthesis in addition to bone marrow aspiration (two patients). All aspirates were evaluated with immunohistochemical studies. Chemotherapy was the only management intervention.
RESULTS: T-cell lymphoma or leukemia accounted for nine cases and Hodgkin's disease for two cases. Respiratory symptoms occurred in 10 patients, including tracheal compression in six patients (compression was life-threatening in one patient). Diagnosis of superior vena cava syndrome was achieved in eight patients using surface-marker analysis of aspirates. The syndrome disappeared within 2 to 10 days. Seven of nine children whose conditions were diagnosed more than 1 year before this writing were alive and free of disease after mean follow-up of 37 months.
CONCLUSIONS: (1) A specific diagnosis can be achieved in most children with superior vena cava syndrome and lymphoma; (2) Thoracic computed tomographic scans are essential, identifying minute pleural effusions that can aid diagnosis; (3) Anesthetic hazard is related only to severe tracheal compression; (4) Chemotherapy achieves excellent symptomatic relief; and (5) Long-term survival, without disease, is achievable.

Entities:  

Mesh:

Year:  1992        PMID: 1514552     DOI: 10.1001/archpedi.1992.02160210062022

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN: 0002-922X


  8 in total

Review 1.  [Diagnostic and therapeutic management of the superior vena cava syndrome].

Authors:  W Dempke; C Behrmann; C Schöber; T Büchele; A Grothey; H J Schmoll
Journal:  Med Klin (Munich)       Date:  1999-12-15

2.  Successful treatment of malignant superior vena cava syndrome using a stent-graft.

Authors:  Dong Il Gwon; Sang Hyun Paik
Journal:  Korean J Radiol       Date:  2012-03-07       Impact factor: 3.500

3.  Superior vena cava syndrome.

Authors:  L S Arya; Sunil Narain; Sanjay Tomar; Vasantha Thavaraj; R Dawar; M Bhargawa
Journal:  Indian J Pediatr       Date:  2002-04       Impact factor: 1.967

4.  Clinical and diagnostic imaging findings predict anesthetic complications in children presenting with malignant mediastinal masses.

Authors:  Doralina L Anghelescu; Laura L Burgoyne; Tiebin Liu; Chin-Shang Li; Ching-Hon Pui; Melissa M Hudson; Wayne L Furman; John T Sandlund
Journal:  Paediatr Anaesth       Date:  2007-11       Impact factor: 2.556

5.  Superior vena cava syndrome in children.

Authors:  Vineeta Gupta; Srikanth R Ambati; P Pant; Baldev Bhatia
Journal:  Indian J Hematol Blood Transfus       Date:  2008-05-01       Impact factor: 0.900

6.  A retrospective stenting study on superior vena cava syndrome caused by lung cancer.

Authors:  Sen Wei; Jinghao Liu; Xin Li; Zuoqing Song; Ming Dong; Honglin Zhao; Qingchun Zhao; Gang Chen; Jun Chen
Journal:  Thorac Cancer       Date:  2020-05-21       Impact factor: 3.500

7.  Hodgkin Lymphoma-Associated Superior Vena Cava Syndrome: A Case Report and Review of the Literature.

Authors:  Ruoning Ni; Mahmoud Amr; Abhishek Kalla
Journal:  Am J Case Rep       Date:  2021-04-10

8.  Significance of pleural effusion at diagnosis in pediatric Hodgkin lymphoma: a report from Children's Oncology Group protocol AHOD0031.

Authors:  Kathleen M McCarten; Monika L Metzger; Richard A Drachtman; Qinglin Pei; Debra L Friedman; Cindy L Schwartz; Kara M Kelly
Journal:  Pediatr Radiol       Date:  2018-07-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.